Comparative Studies of an Orally-active Factor Xa Inhibitor, YM-60828, with other Antithrombotic Agents in a Rat Model of Arterial Thrombosis

Summary

We examined the antithrombotic activity of a novel synthetic inhibitor of factor Xa, YM-60828, in an electrically-induced carotid artery thrombosis model in rats. In the first experiment, the antithrombotic activity of YM-60828 after i.v. infusion was compared with those of heparin, darteparin and argatroban. Test drug was administered by i.v. infusion from 30 min before electrical stimulation to the end of the experiment. YM-60828 at 1 mg/kg/h significantly improved patency status, prolonged the time to occlusive thrombus formation and duration of patency. Heparin at 300 U/kg/h also improved these parameters, but were accompanied by a marked increase in systemic coagulation time. In the second experiment, the antithrombotic activity of YM-60828 after oral administration was compared with those of ticlopidine, cilostazol, aspirin, beraprost, ethyl icosapentate and warfarin. Test drug was orally administered to fasted rats 60 min before electrical stimulation. YM-60828 at 30 mg/kg p.o., but not ticlopidine, cilostazol, aspirin, beraprost, ethyl icosapentate or warfarin, significantly reduced the incidence of occlusion and improved carotid arterial patency. These results suggest that YM-60828 may be a promising antithrombotic agent for the treatment and prevention of arterial thrombosis which can be given by oral as well as intravenous administration.

• References

• 1 Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324: 1865-75.
• 2 Damus PS, Hicks M, Rosenberg RD. Anticoagulant action of heparin. Nature 1973; 246: 355-7.
• 3 Cadroy Y, Harker LA, Hanson SR. Inhibition of platelet-dependent thrombosis by low molecular weight heparin (CY222): comparison with standard heparin. J Lab Clin Med 1989; 114: 349-57.
• 4 Hara H, Tamao Y, Kikumoto R, Okamoto S. Effect of a synthetic thrombin inhibitor MCI-9038 on experimental models of disseminated intravascular coagulation in rabbits. Thromb Haemost 1987; 57: 165-70.
• 5 Broersma RJ, Kutcher LW, Heminger EF. The effect of thrombin inhibition in a rat arterial thrombosis model. Thromb Res 1991; 64: 405-12.
• 6 Freedman MD. Oral anticoagulants: Pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol 1992; 32: 196-209.
• 7 Biggs R, Bangham DR. Standardization of the one-stage prothrombin time test for the control of anticoagulant therapy: the availability and use of thromboplastin reference preparations. Am J Clin Pathol 1972; 57: 117-8.
• 8 O’Reilly RA. The pharmacodynamics of the oral anticoagulant drugs. Prog Hemost Thromb 1974; 2: 175-213.
• 9 Tapparelli C, Metternich R, Ehrhardt C, Cook NS. Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile. TiPS 1993; 14: 366-76.
• 10 Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs 1995; 49: 856-84.
• 11 Vu T-KH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-68.
• 12 Maffrand JP. Direct thrombin inhibitors. Nouv Rev Fr Hematol 1992; 34: 405-19.
• 13 Yin ET. Investigation of the apparent thrombogenicity of heparin. Thromb Diath Haemorrh 1968; 20: 465-8.
• 14 Fioravanti C, Burkholder D, Francis B, Siegl PK, Gibson RE. Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis. Thromb Res 1993; 71: 317-24.
• 15 Hara T, Yokoyama A, Tanabe K, Ishihara H, Iwamoto M. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb Haemost 1995; 74: 635-9.
• 16 Hara T, Yokoyama A, Ishihara H, Yokoyama Y, Nagahara T, Iwamoto M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost 1994; 71: 314-9.
• 17 Yamazaki M, Asakura H, Aoshima K, Saito M, Jokaji H, Uotani C, Kumabashiri I, Morishita E, Ikeda T, Matsuda T. Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats. Thromb Haemost 1994; 72: 393-6.
• 18 Morishita K, Wada M, Kumada T, Tanaka T, Tomikawa M, Iwamoto M. Effect of ticlopidine and other antithrombotics on the venous thrombosis induced by endothelial damage of jugular vein in rats. Thromb Res 1991; 63: 373-84.
• 19 Narita H, Kaburaki M, Doi H, Yasoshima A, Murata S. Antithrombotic effect of TA-993, a novel 1,5-benzothiazepine derivative, in conscious rats. Jpn J Pharmacol 1995; 68: 397-404.
• 20 Imura Y, Kiyota Y, Nagai Y, Nishikawa K, Terashita Z. Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model. Thromb Res 1995; 79: 95-107.
• 21 Nishio S, Matsuura H, Kanai N, Fukatsu Y, Hirano T, Nishikawa N, Kameoka K, Umetsu T. The in vivo and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species. Jpn J Pharmacol 1988; 47: 1-10.
• 22 Sato M, Katsuki Y, Fukuhara K, Kawano H, Mizota M, Hamada Y, Kunihiro Y. Effects of highly purified ethyl all-cis-5,8,11,14,17-icosapentaenoate (EPA-E) on rabbit platelets. Biol Pharm Bull 1993; 16: 362-7.
• 23 Smith GF, Neubauer BL, Sundboom JL, Best KL, Goode RL, Tanzer LR, Merriman RL, Frank JD, Herrmann RG. Correlation of the in vivo anticoagulant, antithrombotic, and antimetastatic efficacy of warfarin in the rat. Thromb Res 1988; 50: 163-74.
• 24 Hladovec J. Experimental thrombosis in rats with continuous registration. Thromb Diath Haemorrh 1971; 26: 407-10.
• 25 Kawasaki T, Kawamura S, Katoh S, Takenaka T. Experimental model of carotid artery thrombosis in rats and the thrombolytic activity of YM866, a novel modified tissue-type plasminogen activator. Jpn J Pharmacol 1993; 63: 135-40.
• 26 Schumacher WA, Steinbacher TE, Heran CL, Megill JR, Durham SK. Effects of antithrombotic drugs in a rat model of aspirin-insensitive arterial thrombosis. Thromb Haemost 1993; 69: 509-14.
• 27 Philip RB, Francey I, Warren BA. Comparison of antithrombotic activity of heparin, ASA, sulfinpyrazone and VK744 in a rat model of arterial thrombosis. Haemostasis 1978; 7: 282-93.
• 28 Schaffer LW, Davidson JT, Vlasuk GP, Dunwiddie CT, Siegl PK. Selective factor Xa inhibition by recombinant antistasin prevents vascular graft thrombosis in baboon. Arterioscler Thromb 1992; 12: 879-85.
• 29 Biemond BJ, Friederich PW, Levi M, Vlasuk GP, Buller HR, ten Cate JW. Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis. Circulation 1996; 93: 153-60.
• 30 Wong PC, Crain Jr EJ, Nguan O, Watson CA, Racanelli A. Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis. Thromb Res 1996; 83: 117-26.
• 31 Yamashita T, Tsuji T, Matsuoka A, Giddings JC, Yamamoto J. The anti-thrombotic effect of synthetic low molecular weight human factor Xa inhibitor, DX-9065a, on He-Ne laser-induced thrombosis in rat mesenteric microvessels. Thromb Res 1996; 85: 45-51.
• 32 Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg 1988; 208: 227-40.
• 33 Mant MJ, O’Brien BD, Thong KL, Hammond GW, Birtwhistle RV, Grace MG. Haemorrhagic complications of heparin therapy. Lancet 1977; 1: 1133-5.
• 34 Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic anti-thrombin D-phenylalanyl-L-prolyl-L-arginyl-chloromethyl ketone (FPRCH₂Cl). Proc Natl Acad Sci USA 1988; 85: 3184-8.
• 35 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.
• 36 Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci USA 1989; 86: 3619-23.
• 37 Holmer E, Mattsson C, Nilsson S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res 1982; 25: 475-85.
• 38 Bergqvist D, Nilsson B, Hedner U, Pedersen PC, Ostergaard PB. The effect of heparin fragments of different molecular weights on experimental thrombosis and haemostasis. Thromb Res 1985; 38: 589-601.
• 39 Zoldhelyi P, Bichler J, Owen WG, Grill DE, Fuster V, Mruk JS, Chesebro JH. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Circulation 1994; 90: 2671-8.
• 40 Berry CN, Girard D, Lochot S, Lecoffre C. Antithrombotic actions of artgatroban in rat models of thrombosis, ‘mixed’ and arterial thrombosis, and its effects on the tail transaction bleeding time. Br J Pharmacol 1994; 113: 1209-14.
• 41 Coccheri S, Palareti G, Fortunato G. Antithrombotic drugs in peripheral obliterative arterial diseases. Haemostasis 1994; 24: 118-27.
• 42 Easton JD. Antiplatelet therapy in the prevention of stroke. Drugs 1991; 42: 39-50.
• 43 Geraets DR, Kienzle MG. Atrial fibrillation and atrial flutter. Clin Pharm 1993; 12: 721-35.
• 44 Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Eng J Med 1988; 318: 1162-73.
• 45 Sila CA. Prophylaxis and treatment of stroke. Drugs 1993; 45: 329-37.